TCT-237 Efficacy and Safety of Routine Thrombus Aspiration in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: an updated Systematic Review and Meta-Analysis of Randomized Controlled Trials  by Mastoris, Ioannis et al.
B92 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5Cardiac magnetic resonance was performed 4-6 days after PCI to
determine infarct size and IMH. In 23 Yorkshire swine, the circumﬂex
coronary artery was occluded for 75 minutes by a balloon catheter.
rADAMTS13 or vehicle was administered intracoronary following
reperfusion. Myocardial injury and infarct characteristics were
assessed using cardiac enzymes, ECG, and histopathology.
RESULTS In patients with IMH, VWF activity and VWF antigen were
signiﬁcantly elevated directly after PCI and for all subsequent mea-
surements, and ADAMTS13 activity signiﬁcantly decreased at 4 and 7
days following PCI; in comparison to patients without IMH. VWF ac-
tivity and ADAMTS13 activity were not related to infarct size. For
rADAMTS13 treated animals no differences in myocardial infarct size,
IMH, or formation of microthrombi were witnessed in comparison to
controls.
CONCLUSIONS No correlation was witnessed between VWF/
ADAMTS13 and infarct size in patients; and intracoronary adminis-
tration of rADAMTS13 did not decrease infarct size or IMH in a porcine
model of myocardial ischemia-reperfusion. These data dispute the
imbalance in ADAMTS13 and VWF as the cause of no reﬂow. Restoring
the imbalance between ADAMTS13 and VWF most likely will not be
beneﬁcial in STEMI patients already treated with standard antiplatelet
and anticoagulant therapy.
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BACKGROUND Randomized clinical trials evaluating the role of
thrombus aspiration (TA) in patients undergoing primary percuta-
neous coronary intervention (PPCI) for ST-segment elevation
myocardial infarction (STEMI) have yielded contrasting results.
Therefore, the efﬁcacy and safety of TA in STEMI is unclear.
METHODS We included study-level data from 25 randomized
controlled trials (RCTs), involving 21,733 patients with STEMI and
PPCI. The primary efﬁcacy endpoint was MACE according to study
deﬁnitions; the primary safety endpoint was stroke. We sought to
evaluate the efﬁcacy and safety of TA during PPCI for STEMI
compared with conventional PPCI alone.
RESULTS The mean weighted follow-up time across studies was 8.2
months. Compared with conventional PPCI, TA was associated with
signiﬁcant lower risk for MACE (Relative Risk [RR]: 0.91; 95% Conﬁ-
dence Interval [CI]: 0.83 – 1.00; p ¼ 0.042). However, this beneﬁt in
MACE was counterbalanced by a signiﬁcant increase in the risk for
stroke (RR: 1.58; 95% CI: 1.11 – 2.25; p ¼ 0.011). There were no differ-
ences in the risk of myocardial infarction (RR: 0.94; 95% CI: 0.78 – 1.12;p ¼ 0.486), target vessel revascularization (RR: 0.93; 95% CI: 0.82 –
1.04; p ¼ 0.2) and deﬁnite or probable stent thrombosis (RR: 0.84; 95%
CI: 0.66 – 1.07; p ¼ 0.148). TA was associated with an ostensible lower
risk for all-cause mortality, which did not reach statistical signiﬁcance
(RR: 0.88; 95% CI: 0.78 – 1.00; p ¼ 0.059).
CONCLUSIONS Compared with conventional PPCI for STEMI,
adjunctive TA reduces the risk of subsequent MACE. However, the
beneﬁt in MACE is counterbalanced by an increased risk in stroke.
Considering the above potential risks and beneﬁts, TA should be
considered in selected patients lesions rather than routinely.
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BACKGROUND Prior studies have found that smokers with ST-
segment elevation myocardial infarction (STEMI) have lower rates of
mortality and adverse events. This phenomenon has been called “the
smoker’s paradox.” We sought to investigate the impact of smoking
